CA2545723A1 - Use of cathepsin k inhibitors in severe bone loss diseases - Google Patents

Use of cathepsin k inhibitors in severe bone loss diseases Download PDF

Info

Publication number
CA2545723A1
CA2545723A1 CA002545723A CA2545723A CA2545723A1 CA 2545723 A1 CA2545723 A1 CA 2545723A1 CA 002545723 A CA002545723 A CA 002545723A CA 2545723 A CA2545723 A CA 2545723A CA 2545723 A1 CA2545723 A1 CA 2545723A1
Authority
CA
Canada
Prior art keywords
lower alkyl
aryl
cathepsin
bone
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002545723A
Other languages
English (en)
French (fr)
Inventor
Martin Missbach
Rainer Gamse
Ulrich Trechsel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2545723A1 publication Critical patent/CA2545723A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002545723A 2003-11-19 2004-04-19 Use of cathepsin k inhibitors in severe bone loss diseases Abandoned CA2545723A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03026430 2003-11-19
EP03026430.3 2003-11-19
PCT/EP2004/004155 WO2005049028A1 (en) 2003-11-19 2004-04-19 Use of cathepsin k inhibitors in severe bone loss diseases

Publications (1)

Publication Number Publication Date
CA2545723A1 true CA2545723A1 (en) 2005-06-02

Family

ID=34610055

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002545723A Abandoned CA2545723A1 (en) 2003-11-19 2004-04-19 Use of cathepsin k inhibitors in severe bone loss diseases

Country Status (16)

Country Link
US (1) US20070135448A1 (pt)
EP (1) EP1686995A1 (pt)
JP (1) JP2007511548A (pt)
KR (1) KR20060107792A (pt)
CN (1) CN1882343A (pt)
AU (1) AU2004290874A1 (pt)
BR (1) BRPI0416755A (pt)
CA (1) CA2545723A1 (pt)
IL (1) IL175436A0 (pt)
IS (1) IS8498A (pt)
MA (1) MA28174A1 (pt)
MX (1) MXPA06005635A (pt)
NO (1) NO20062870L (pt)
TN (1) TNSN06147A1 (pt)
TW (1) TW200526198A (pt)
WO (1) WO2005049028A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
US20080076723A1 (en) * 2006-09-27 2008-03-27 Sylvan Pharmaceuticals Pty Ltd. Inhibition of cathepsin K activity and the treatment and prevention of disease
BRPI0808046A2 (pt) 2007-02-28 2014-07-08 Sanofi Aventis Sondas de imageamento

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841871D1 (en) * 1997-11-05 2010-10-14 Novartis Ag Dipeptide nitrile
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
JP3892187B2 (ja) * 1998-11-12 2007-03-14 生化学工業株式会社 環状アミド誘導体
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
US20060281714A1 (en) * 2003-07-21 2006-12-14 Johann Zimmermann Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss

Also Published As

Publication number Publication date
IL175436A0 (en) 2008-04-13
JP2007511548A (ja) 2007-05-10
IS8498A (is) 2006-06-06
MXPA06005635A (es) 2006-08-17
US20070135448A1 (en) 2007-06-14
MA28174A1 (fr) 2006-09-01
AU2004290874A1 (en) 2005-06-02
EP1686995A1 (en) 2006-08-09
NO20062870L (no) 2006-08-18
WO2005049028A1 (en) 2005-06-02
TW200526198A (en) 2005-08-16
KR20060107792A (ko) 2006-10-16
TNSN06147A1 (en) 2007-11-15
CN1882343A (zh) 2006-12-20
BRPI0416755A (pt) 2007-02-27

Similar Documents

Publication Publication Date Title
AU2003217961B2 (en) Combination therapy for treating, preventing or managing proliferative disorders and cancers
CN101583359B (zh) 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮在套细胞淋巴瘤治疗中的用途
CN103142594A (zh) 使用3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮治疗某些白血病的方法
ZA200503927B (en) Pharmaceutical compositions and dosage forms of thalidomide
US20100129363A1 (en) Methods and compositions using pde4 inhibitors for the treatment and management of cancers
TWI721136B (zh) 特定苯並二氫呋喃類木脂素於抑制乳癌細胞轉移之用途
NZ564480A (en) Use of selective cytokine inhibitory drugs for the treatment of Behcet's disease
EP2134341B1 (en) Method of treating cell proliferative disorders using growth hormone secretagogues
US20090048157A1 (en) Use of organic compounds
WO2004080445A1 (en) Methods and compositions for the treatment of cancer
US20070135448A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
EP2504703B1 (en) Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
WO2004065572A2 (en) Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis
AU2004288715A1 (en) Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders
KR20090061358A (ko) 아카세틴을 유효성분으로 하는 유방암 예방 및 치료용조성물
WO2007143096A2 (en) Compounds for treating cancers
ZA200407150B (en) Combination therapy for treating, preventing or managing proliferative disorders and cancer.
KR20090061356A (ko) 제니스테인을 포함하는 유방암 치료 및 예방용 조성물
MXPA06004999A (en) Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders

Legal Events

Date Code Title Description
FZDE Discontinued